Linkedin
SCIRENT: Advancing cardiovascular research for a healthier tomorrow
Get in touch

Advancing Biopharmaceuticals
and Medical Technologies
in Cardiovascular Medicine

COVID-19 Keeping up trial safety and progress

Learn more
Services

Accelerate Your Research in Cardiovascular Trials

is a full-service contract research organization (CRO) specialized in cardiovascular research. Our services cover the whole spectrum of development.

Learn more
References

We Share Your Enthusiasm for Finding Effective Therapies

works with biopharmaceutical and medical technology companies across all phases of development. Our deep expertise in cardiovascular medicine makes us a strong partner for your cardiovascular trials.

Learn more
About

Together We Find the Right Solution

Accessible and responsive leadership, dedicated staff, and a specialized site network – this is how we help study sponsors develop innovative therapies.

Learn more
References

Clients & Partners

BLOG

Discover the latest updates on cardiovascular research

Press release

Prof. Dr. Wilhelm Haverkamp Appointed Chief Medical Officer at SCIRENT

Wiebke Lesch 16. April 2026
Berlin, 16. April 2026. SCIRENT announced the appointment of Prof. Dr. Wilhelm Haverkamp as Chief Medical Officer (CMO), effective immediately. In this role, Prof. Haverkamp will further strengthen SCIRENT’s medical and scientific leadership and expand the company’s activities in drug...
CSI Focus D-HF
Conferences

SCIRENT to Participate in CSI Focus D-HF 2025 in Frankfurt

Wiebke Lesch 26. November 2025
SCIRENT, a full-service cardiovascular Contract Research Organization (CRO) specializing in clinical studies for heart failure and cardiac devices, will participate in the upcoming CSI Focus D-HF 2025, taking place December 5–6, 2025, in Frankfurt, Germany. The conference is the leading...
Prof. Dr. Thomas Bernd Dschietzig, CEO of Relaxera, and Prof. Dr. Hans-Dirk Düngen, CEO of SCIRENT, at the SCIRENT booth during ESC 2025 in Madrid. The two experts discuss the SOURCE-HF phase 2 clinical trial investigating relaxin-2 in heart failure.
Conferences

SOURCE-HF Phase 2 Study – collaboration announcement between Relaxera and Scirent

Angelika Gaufer 1. September 2025
A behind-the-scenes look at ESC 2025 in Madrid At this year’s European Society of Cardiology (ESC) Congress in Madrid, the spotlight was not only on cutting-edge research and innovation in cardiovascular medicine. One of the highlights at the SCIRENT booth was a video...
View all
Book a meeting

Thank you for your application.

We will get in touch shortly.

Thank you. Your data was submitted successfully.

We will get in touch shortly.